Cardiology
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology
Genetics
Geriatrics/Aging
Hematology/Oncology
Immunology/Allergy
Infectious Disease
Nephrology
Neurology/Neurosurgery
Obstetrics/Gynecology
Pediatrics
Psychiatry
Public Health, Policy, and Training
Pulmonary
Rheumatology
Surgery

Nejm News Une Mise à Jour The New England Journal of Medicine by Specialties

 


The New England Journal of Medicine: Search Results in Hematology\Oncology
The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Hematology\Oncology. NEJM (http://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice.

Orbital Apex Syndrome
01/01/70 - A 61-year-old man presented to the emergency department with a 3-week history of right retro-orbital pain and a 1-week history of double vision, lid droop, and loss of vision. Ophthalmologic examination revealed reduced vision in the right eye (only hand motion was perceived), a relative afferent…

Colon Cutoff Sign
01/01/70 - A 74-year-old woman presented to the emergency department with a 3-day history of lower abdominal pain, nausea, and vomiting. She had been unable to pass any stool for 1 week and reported having had small-caliber stool during the previous 6 months. On physical examination, bowel sounds were…

The Long Ride Home
01/01/70 - The loud, unwieldy bipap machine seemed to smother Hannah as she was wheeled out of the pediatric ICU for the last time. The apparatus thrust air into her leukemia-riddled lungs with such force it was hard to tell whether she had anything to do with the mechanical, rhythmic rise and fall of her…

Prostate Cancer Metastasis ? Fueled by Fat?
01/01/70 - Obesity is approaching epidemic proportions worldwide and is having an effect on many chronic illnesses, including cancer. The physiological consequences of obesity include a state of chronic inflammation, which has been associated with an increased risk of development of cancer or of progression…

Gene Therapy in Patients with Transfusion-Dependent ?-Thalassemia
01/01/70 - The ?-hemoglobinopathies, which include ?-thalassemia and sickle cell disease, are among the most prevalent monogenic disorders worldwide. ?-thalassemia is caused by more than 200 mutations in the HBB globin gene, which encodes the beta subunit of the most common form of adult hemoglobin, HbA.…

Gene Therapy as a Curative Option for ?-Thalassemia
01/01/70 - With an estimated global prevalence of 288,000 cases, ?-thalassemia is one of the most common genetic diseases in the world, and every year another 60,000 infants are born with the disease. Of these patients, 60 to 80% have a severe form of the disease and require regular red-cell transfusions and…

Pembrolizumab plus Chemotherapy in Metastatic Non?Small-Cell Lung Cancer
01/01/70 - Inhibitors of programmed death 1 (PD-1) and its ligand PD-L1 are effective therapies for metastatic non?small-cell lung cancer (NSCLC) lacking sensitizing EGFR or ALK mutations. Pembrolizumab (Keytruda, Merck), nivolumab (Opdivo, Bristol-Myers Squibb), and atezolizumab (Tecentriq, Genentech) are…

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
01/01/70 - Standard-of-care therapy for previously untreated advanced non?small-cell lung cancer (NSCLC) without treatable driver mutations includes platinum-based chemotherapy and pembrolizumab for patients with a high level (?50%) of tumor programmed death ligand 1 (PD-L1) expression. There remains a need…

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
01/01/70 - Antibodies that block the immune inhibitory pathway of programmed death 1 (PD-1) protein have provided a major treatment advance in patients with cancer. In some patients with advanced non?small-cell lung cancer (NSCLC), these drugs unleash antitumor immunity, resulting in tumor regression and…

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
01/01/70 - The development of effective adjuvant therapies for patients with high-risk melanoma has been preceded by the recent arrival of active agents to treat metastatic melanoma, including ipilimumab (an anti-CTLA4 antibody), pembrolizumab and nivolumab (both monoclonal antibodies against programmed death…

Copyright © 2004/2011 Health.Cat

Annuaire de Sante | S'inscrire au MedSante  | Dictionnaire medicale  Forumed des médecins